The inherent ethical challenge of first-in-human pluripotent stem cell trials

Regenerative Medicine

Volumn 9, Issue 1, 2014, Pages 1-3

  Habets, Michelle G J L ^a   Van Delden, Johannes J M ^a   Bredenoord, Annelien L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

ethics; first in human trials; induced pluripotent stem cells; iPS cells; pluripotent stem cells; research ethics; risk benefit; social value; translational medicine

Indexed keywords

BLOOD EYE BARRIER; CANCER RISK; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); EMBRYONIC STEM CELL; EPIGENETICS; FIRST IN HUMAN STUDY; GENE MUTATION; GENE TRANSFER; HUMAN; MEDICAL ETHICS; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIGMENT EPITHELIUM; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; RETINA MACULA DEGENERATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SOCIAL PSYCHOLOGY; STEM CELL TRANSPLANTATION; VULNERABLE POPULATION;

CLINICAL TRIALS AS TOPIC; HUMANS; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; RISK MANAGEMENT; STEM CELL RESEARCH;

EID: 84891070491     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.13.83     Document Type: Review

References (15)

1. Schwartz SD, Hubschman JP, Heilwell G et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379(9817), 713-720 (2012)
2. Takahashi K, Tanabe K, Ohnuki Met al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007) (Pubitemid 350138099)
3. Tibbetts MD, Samuel MA, Chang TS, Ho AC. Stem cell therapy for retinal disease. Curr. Opin. Opthalmol. 23, 226-234 (2012)
4. Wilson JM. A History lesson for stem cells. Science 324, 727-728 (2009)
5. Rid A, Wendler D. A framework for risk-benefit evaluations in biomedical research. Kennedy Inst. Ethics J. 21, 141-179 (2011)
6. Kimmelman J. The ethics of human gene transfer. Nat. Rev. Genet. 9, 239-244 (2008) (Pubitemid 351271801)
7. Niemansburg SL, van Delden JJ, Dhert WJ, Bredenoord AL. Regenerative medicine interventions for orthopedic disorders: ethical issues in the translation into patients. Regen. Med. 8, 65-73 (2013)
8. Pera MF. Stem cells. The dark side of induced pluripotency. Nature 471, 46-47 (2011)
9. Pryzhkova MV. Stem cells: will they ever be the same? Regen. Med. 8, 97-99 (2013)
10. Kiefer JC. Primer and interviews: promises and realities of induced pluripotent stem cells. Dev. Dyn. 240, 2034-2041 (2011)
11. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 481, 295-305 (2012)
12. Fleming TR, Demets DL. Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. 125, 605-613 (1996) (Pubitemid 126450094)
13. Horng S, Grady C. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB 25(1), 11-16 (2003) (Pubitemid 41585063)
14. Isasi R, Knoppers BM, Andrews PW et al. Disclosure and management of research findings in stem cell research and banking: policy statement. Regen. Med. 7, 439-448 (2012)
15. Bredenoord AL, Braude P. Ethics of mitochondrial gene replacement: from bench to bedside. BMJ 341, c6021 (2010).